Viridian Therapeutics (VRDN) 10-K 21 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 15, 2016	Jun. 30, 2015
Entity Registrant Name	SIGNAL GENETICS, INC.
Entity Central Index Key	1,590,750
Trading Symbol	sgnl
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,709,080
Entity Public Float			$ 11.6
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$ 10,832,000	$ 5,119,000
Accounts receivable, net	394,000	1,088,000
Inventory	187,000	179,000
Prepaid expenses and other current assets	321,000	399,000
Total current assets	11,734,000	6,785,000
Property and equipment, net	$ 1,153,000	1,214,000
Deferred offering costs		47,000
Security deposits	$ 15,000	43,000
Total assets	12,902,000	8,089,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	242,000	255,000
Accrued liabilities	1,018,000	$ 361,000
Note payable – related party	$ 1,105,000
Amounts due to related party		$ 1,045,000
Lease termination/abandonment payable - current portion		248,000
Other current liabilities	$ 103,000	80,000
Total current liabilities	2,468,000	1,989,000
Other noncurrent liabilities	$ 24,000	$ 109,000
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2015 or 2014	$ 0	$ 0
Common stock, $0.01 par value, 50,000,000 shares authorized, 10,635,454 and 3,782,629 shares issued and outstanding at December 31, 2015 and 2014, respectively	106,000	38,000
Additional paid in capital	28,272,000	12,593,000
Accumulated deficit	(17,968,000)	(6,640,000)
Total stockholders’ equity	10,410,000	5,991,000
Total liabilities and stockholders’ equity	$ 12,902,000	$ 8,089,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Preferred Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Common Stock, Shares Issued (in shares)	10,635,454	3,782,629
Common Stock, Shares Outstanding (in shares)	10,635,454	3,782,629

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Predecessor [Member]
Operating expenses:
Net loss		$ (1,250,000)
Successor [Member]
Operating expenses:
Net loss	$ (11,328,000)	(6,640,000)
Net revenue	2,538,000	4,320,000
Cost of revenue	2,472,000	3,366,000
Research and development	1,002,000	347,000
Selling and marketing	2,559,000	717,000
General and administrative	$ 7,692,000	6,857,000
Gain on legal settlement		(100,000)
Total operating expenses	$ 13,725,000	11,187,000
Loss from operations	(11,187,000)	(6,867,000)
Interest expense	(141,000)	(1,023,000)
Net loss	$ (11,328,000)	$ (7,890,000)
Net loss per common share, basic and diluted (in dollars per share)	$ (1.40)	$ (3.50)
Weighted-average number of shares outstanding, basic and diluted (in shares)	8,091,899	2,255,864

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity and Members' Deficiency - USD ($)		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Capital Units [Member]Capital Unit, Class A [Member]	Capital Units [Member]Capital Unit, Class B [Member]	Capital Units [Member]Capital Unit, Class C [Member]	Member's Deficiency [Member]		Capital Unit, Class C [Member]	Total
Balance (in shares) at Dec. 31, 2013					72,500	41,088
Balance at Dec. 31, 2013	[1]							$ (23,887,000)
Conversion of note payable to Class C Units (in shares)							2,732,629
Conversion of note payable to Class C Units								27,326,000	[1]	$ 27,326,000
Net loss | Predecessor [Member]								(1,250,000)	[1]		$ (1,250,000)
Net loss | Successor [Member]				$ (6,640,000)							(6,640,000)
Net loss											(7,890,000)
Stock Issued During Period, Shares, Conversion of Units		2,932,629			(72,500)	(41,088)	(2,732,629)
Conversion from Limited Liability Company to Corporation		$ 29,000	$ 2,160,000					$ (2,189,000)	[1]		2,189,000
Stock Issued During Period, Shares, New Issues		850,000
Public offering of common stock, net of costs to issue		$ 9,000	5,835,000								5,844,000
Issuance of Stock and Warrants for Services or Claims			300,000								300,000
Stock-based compensation			4,298,000								4,298,000
Balance (in shares) at Dec. 31, 2014		3,782,629
Balance at Dec. 31, 2014		$ 38,000	12,593,000	$ (6,640,000)							$ 5,991,000
Conversion of note payable to Class C Units
Net loss | Predecessor [Member]
Net loss | Successor [Member]											$ (11,328,000)
Net loss				(11,328,000)							(11,328,000)
Stock Issued During Period, Shares, New Issues		6,431,410
Public offering of common stock, net of costs to issue		$ 64,000	12,701,000								12,765,000
Issuance of Stock and Warrants for Services or Claims			330,000								330,000
Stock-based compensation			3,015,000								3,015,000
Balance (in shares) at Dec. 31, 2015		10,635,454
Balance at Dec. 31, 2015		$ 106,000	28,272,000	$ (17,968,000)							10,410,000
Shares issued under employee stock incentive plan, net of shares repurchased to satisfy tax withholding obligations (in shares)		421,415
Shares issued under employee stock incentive plan, net of shares repurchased to satisfy tax withholding obligations		$ 4,000	$ (367,000)								$ 363,000
[1]	Members' deficiency was reclassified to additional paid-in capital upon conversion from the Limited Liability Company to the Corporation.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
From Related Party Payable to Note Payable - Related Party [Member]
Noncash investing and financing activities:
Conversion of amounts due to related party to note payable – related party	$ 1,045,000
Capital Unit, Class C [Member]
Noncash investing and financing activities:
Conversion of note payable to Class C Units		$ 27,326,000
Net loss	$ (11,328,000)	(7,890,000)
Stock-based compensation	3,015,000	4,298,000
Depreciation and amortization	184,000	144,000
Noncash interest on note payable – related party	$ 132,000	1,007,000
Lease termination		46,000
Gain on legal settlement		(100,000)
Accounts receivable	$ 694,000	(94,000)
Inventory	(8,000)	178,000
Prepaid expenses and other current assets	28,000	191,000
Accounts payable and accrued liabilities	633,000	383,000
Lease termination/abandonment payable	(248,000)	(376,000)
Net cash used in operating activities	(6,898,000)	(2,213,000)
Purchases of property and equipment	(123,000)	(266,000)
(Increase) decrease in security deposit on lease	28,000	(8,000)
Net cash used in investing activities	(95,000)	(274,000)
Proceeds from issuances of common stock, net of costs to issue	13,095,000	6,644,000
Proceeds from issuance of note payable/amounts due to related party		$ 795,000
Proceeds from cash released from restricted cash account securing a letter of credit	50,000
Shares repurchased to satisfy tax withholding obligation for restricted stock awards	(363,000)
Repayment of capital lease obligation and note payable	(76,000)	$ (42,000)
Net cash provided by financing activities	12,706,000	7,397,000
Net increase in cash	5,713,000	4,910,000
Cash and cash equivalents, beginning of period	5,119,000	209,000
Cash and cash equivalents, end of period	10,832,000	5,119,000
Cash paid for interest	6,000	1,000
Fair value of warrants and options for overallotment shares to underwriters issued in connection with public stock offerings	$ 330,000	300,000
Asset acquired under capital lease		$ 164,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Basis of Presentation Signal Genetics, Inc. (the “Company”) is a commercial stage, molecular genetic diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. In 2010, the Company became the exclusive licensee to the intellectual property stemming from the renowned research on multiple myeloma (“MM”), performed at the University of Arkansas for Medical Sciences (“UAMS”). Myeloma Prognostic Risk Signature (“MyPRS ® ® Basis of Presentation and Liquidity The accompanying consolidated financial statements include the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Since its inception, the Company has devoted substantial effort in developing its products and services and has incurred losses and negative cash flows from operations. Prior to its IPO, all financial support had been provided by the Company’s majority member. As of December 31, 2015, however, following the ATM program, the 2015 Offering, the Debt Conversion, the Corporate Conversion and the IPO, each as defined below, the Company has positive working capital and stockholders’ equity. Although the Company is forecasting continued losses and negative cash flows as it funds its expanding selling and marketing activities, and research and development programs, the Company believes that it has enough cash and cash equivalents on hand to support operations for 12 to 15 months from the date of this report. Going forward, as the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. Public Offerings of Common Stock On July 10, 2015, the Company filed a prospectus for the offering, issuance and sale of securities from time to time in one or more offerings (“Shelf Registration”) which was declared effective by the SEC on July 28, 2015. The amount of securities to be sold pursuant to the Shelf Registration is limited by the Company’s public float. Concurrently with filing the Shelf Registration, the Company entered into a sales agreement with Cantor Fitzgerald & Co., to sell shares of its common stock, with aggregate gross sales proceeds of up to $4.45 million, from time to time, through an “at-the-market” equity offering program (the “ATM program”). During the year ended December 31, 2015, the Company sold 2,734,983 shares of common stock pursuant to this registration for total cash proceeds of $4.0 million, which is net of $429,000 in sales agent’s commissions and offering expenses. Due to the size of the Company’s public float, the current ATM program has been completed, unless and until the Company’s public float increases. On February 20, 2015, the Company completed a public offering (the “2015 Offering”) of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.8 million, which is net of $1.2 million in underwriter commissions and offering expenses. On February 26, 2015, the underwriters exercised their overallotment option for 482,142 additional shares of the Company’s common stock, for total cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions. Corporate Conversion and Initial Public Offering On June 17, 2014, the Company completed a corporate conversion and Signal Genetics LLC converted from a limited liability company to a Delaware corporation (the “Corporate Conversion”). Immediately prior to the Corporate Conversion, $27.3 million of the Company’s note payable — related party was converted into 2,732,629 newly authorized Class C units (the “Debt Conversion”). In connection with the Corporate Conversion, all outstanding Class A and C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for an aggregate of 2,932,629 shares of common stock of the Company, the members of Signal Genetics LLC became stockholders of the Company and the Company succeeded to the business of Signal Genetics LLC and its consolidated subsidiaries. On June 23, 2014, the Company completed an initial public offering (the “IPO”) of 850,000 shares of its common stock, at $10.00 per share, for net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash fair values of warrants and the option for overallotment shares issued in connection with the IPO.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Significant Accounting Policies Use of Estimates The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, accounts receivable and allowance for doubtful accounts, accounting for income taxes, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash is comprised of cash on hand and deposits in banks. The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents, which, at December 31, 2015, are comprised of money market funds. At December 31, 2014, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease. The restriction was removed during 2015 and the cash balance transferred into the Company’s money market account. Accounts Receivable, and Contractual Allowances and Allowance for Doubtful Accounts Accounts receivable are recorded net of contractual allowances and an allowance for doubtful accounts. At December 31, 2015 and 2014, contractual allowances were $2.1 million and $1.5 million, respectively. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. During the years ended December 31, 2015 and 2014, the Company recognized $33,000 and $177,000 in bad debt expense, respectively. At December 31, 2015 and 2014, there were no allowances for doubtful accounts. Inventory Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method. Property and Equipment Property and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in operations. Long Lived Assets Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years ended December 31, 2015 or 2014. Deferred Offering Costs During the year ended December 31, 2014, the Company incurred $47,000 in direct costs related to its anticipated public offering of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and reclassified as a reduction to additional paid-in capital upon completion of the 2015 Offering. Deferred Rent Where rent abatements are made available to the Company under the terms of a lease agreement, the abatements are accounted for as a reduction of rent expense over the life of the lease and rent expense is recognized on a straight-line basis over the entire term of the lease. The cumulative difference between actual rent payments and recognized rental expense is recorded as deferred rent in the consolidated balance sheets. Revenue Recognition Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Revenues are recorded on an accrual basis when the contractual obligations are completed as tests are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced at the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate, and anticipated effects of changes in the healthcare industry, if any. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date. The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and anticipated changes in the healthcare industry and adjusts expected revenues for current and subsequent periods accordingly. During the year ended December 31, 2015, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $193,000. During the year ended December 31, 2014, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000 and $274,000 related to revenues previously recorded during 2012 and 2013, respectively. The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations: Years Ended December 31, (in thousands) 2015 2014 Gross revenues $ 5,706 $ 6,484 Less: contractual allowances (3,168 ) (2,164 ) Net revenue $ 2,538 $ 4,320 Contractual allowances recorded during the years ended December 31, 2015 and 2014 represented 56% and 33% of gross revenues, respectively. The increase in the contractual allowances is due to changes in the Company’s estimates of net revenue for non-contracted payors based on the contractual status and payment policies of the payors, and anticipated changes in the healthcare industry. Cost of Revenue Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result, depreciation, amortization and royalty expense. Costs associated with performing tests are recorded as the tests are processed. Royalties The Company licenses technology for patents for uses of a gene expression profiling (“GEP”) assay called MyPRS ® Research and Development Costs associated with research and development activities are expensed as incurred. Research and development costs primarily include personnel costs, laboratory supplies, reagents, consulting and sponsored research agreements. Income Taxes Prior to the Corporate Conversion, the Company was a limited liability company, which is not a tax paying entity at the corporate level. Each member was instead individually responsible for such member’s share of the Company’s income or loss for income tax reporting purposes. Net operating losses incurred by the Company through the date of the Corporate Conversion have been, or will be, used by the members to offset gains on other interests and are, therefore, not able to be carried forward to the Company. Effective as of the Corporate Conversion, deferred tax assets and liabilities are recorded for the expected future tax consequences of events that have been included in the consolidated financial statements or income tax returns. Deferred taxes are determined on the basis of the differences between the carrying amount of assets and liabilities for financial statement and income tax purposes, as well as tax credit and net operating loss carryforwards, at enacted rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. Applicable accounting guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Accounting provisions also require that a change in judgment that results in subsequent recognition, derecognition, or change in a measurement of a tax position taken in a prior annual period (including any related interest and penalties) be recognized as a discrete item in the period in which the change occurs. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available. Any interest and penalties related to unrecognized tax benefits are classified as a component of income tax expense. Stock-Based Compensation Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees and directors is estimated at the date of grant. The fair value of restricted stock units issued to employees and directors is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. For stock-based compensation awards granted to non-employees, the fair value of the awards are remeasured at each reporting date until vested, with changes in the estimated fair value recognized as an adjustment to compensation expense in the period of change. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense. Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards. Fair Value of Financial Instruments The Company’s financial instruments that are measured at fair value on a recurring basis consist principally of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and note payable-related party. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Includes other inputs that are directly or indirectly observable in the marketplace. Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. At December 31, 2015 and 2014, the Company’s cash equivalent instruments consisted of $10.4 million and $0, respectively, in a money market fund which is reported at fair value using Level 1 inputs. The carrying amounts of financial instruments such as restricted cash, accounts receivable, accounts payable and note payable-related party approximate their relative fair values due to the short-term maturities and market rates of interest of these instruments. At December 31, 2014, the fair value of the Company’s remaining lease liability on its vacated facility, which was paid in full during 2015, was measured using estimated net cash flows, discounted using a nominal risk-free rate, which are considered Level 3 inputs. The present value of the remaining lease liability at December 31, 2014 was $248,000. Net Loss Per Share Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting. Common stock equivalents, determined on a weighted-average outstanding basis, that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows: December 31, 2015 2014 Unvested restricted stock units 431,088 655,200 Options to purchase common stock 355,215 152,000 Warrants to purchase common stock 180,446 42,500 Total 966,749 849,700 Concentration of Credit Risk, Major Customers and Suppliers Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances. The Company invests excess cash in money market funds under the custodianship of a major financial institution. This diversification of risk is consistent with the Company's policy to ensure safety of principal and maintain liquidity. The Company had two major customers, UAMS and H. Lee Moffitt Cancer Center and Research Institute (“Moffitt”). Revenue sourced either from or through UAMS accounted for 54% and 84% of net revenue during the years ended December 31, 2015 and 2014, respectively, and revenue sourced through Moffitt accounted for 10% and 9% of net revenue during the years ended December 31, 2015 and 2014 respectively. Accounts receivable from UAMS at December 31, 2015 and 2014 accounted for 19% and 42%, respectively, of total accounts receivable outstanding. At December 31, 2015 and 2014 the Company had no accounts receivable from Moffitt. Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business. Reclassifications Reclassifications of certain operating expenses in the consolidated statement of operations have been made to year ended December 31, 2014 to conform to the 2015 presentation. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, which replaces the existing accounting guidance for leases. This standard requires entities that lease assets to recognize the assets and liabilities for the rights and obligations created by those leases on the balance sheet. The standard is effective for fiscal years and the interim periods within those fiscal years beginning after December 15, 2018. The guidance is required to be applied by the modified retrospective transition approach and early adoption is permitted. The Company is currently assessing the impact that adoption of this guidance will have on its consolidated financial statements and footnote disclosures. In July 2015, the FASB issued ASU 2015-11, which simplifies the measurement of inventories valued under most methods, including the Company’s inventories valued under the FIFO method. Under this new guidance, inventories valued under these methods would be valued at the lower of cost and net realizable value, with net realizable value defined as the estimated selling price less reasonable costs to sell the inventory. The new guidance is effective prospectively for the Company’s quarterly reporting period beginning January 1, 2017, with early adoption permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and was originally effective for the Company’s annual reporting period beginning January 1, 2018, including interim periods within that reporting period. In July 2015, the FASB voted to defer the effective date of this ASU by one year, which is effective for the Company’s annual reporting period beginning January 1, 2019, with early adoption permitted beginning with the annual reporting period ending December 31, 2017. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period ending December 31, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. Future Accounting Pronouncements Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company, such as the Company, may take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although, to date, the Company has not taken advantage of this delay, the Company has elected to avail itself of the extended transition period for adopting new or revised accounting standards in the future. As a result of this election, the Company’s consolidated financial statements may not be comparable to companies that comply with public company effective dates.

Note 3 - Balance Sheet Accounts

Note 3 - Balance Sheet Accounts and Supplemental Disclosures	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	3. Balance Sheet Accounts and Supplemental Disclosures Property and Equipment Property and equipment consist of the following: December 31, (in thousands) 2015 2014 Laboratory and computer equipment $ 1,817 $ 1,711 Furniture and fixtures 69 52 Leasehold improvements 6 6 1,892 1,769 Less: accumulated depreciation and amortization (739 ) (555 ) Total property and equipment, net $ 1,153 $ 1,214 An asset with a cost of $300,000 recorded under a capital lease is included in the laboratory equipment balance at December 31, 2015 and 2014. Accrued Expenses Accrued expenses consist of the following: December 31, (in thousands) 2015 2014 Accrued bonuses $ 592 $ 183 Accrued compensation and related expenses 234 74 Accrued interest payable – related party 73 — Accrued contract research and development 35 — Accrued offering costs — 42 Other 84 62 Total accrued expenses $ 1,018 $ 361

Note 4 - Amount Due Related Par

Note 4 - Amount Due Related Party, Notes Payable and Capital Lease Obligations	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt and Capital Leases Disclosures [Text Block]	4. Amount Due Related Party, Notes Payable and Capital Lease Obligations Note Payable — Related Party and Amounts Due to Related Party On March 6, 2015, the amounts due to related party, aggregating $1,045,000, were converted into an unsecured note payable – related party, bearing interest at 8% per annum and due on demand. The principal amount of the note was increased by $60,000 over the amounts due to related party to $1,105,000 to provide the equivalent of 8% per annum interest for the period of time the amounts due to related party were held as a payable in exchange for a provision that the related party would not call the note prior to June 30, 2015. The increase in the principal amount of the note was deferred and amortized to interest expense over the initial term of the note to June 30, 2015. Interest expense related to this note during the year ended December 31, 2015 was $132,000. The note balance at December 31, 2015 was $1,105,000 and accrued interest payable of $73,000 is included in accrued liabilities in the consolidated balance sheet at December 31, 2015. During the year ended December 31, 2014, the Company’s then majority member, through various entities controlled by such member, loaned a net amount of $795,000 to the Company to support its operations. Pursuant to the terms of an Exchange Agreement, and prior to the Corporate Conversion, $27.3 million of the Secured Note payable as of June 17, 2014 was exchanged for 2,732,629 Class C units of Signal Genetics LLC and recorded to members’ equity. The remaining $1.0 million as of that date, along with an additional $45,000, which was advanced to pay for certain offering expenses, was reclassified as unsecured amounts due to related party in the consolidate balance sheet. Such amounts due were converted into an unsecured note payable – related party as discussed above. Prior to the Debt Conversion, the Secured Note bore interest at 8% compounded quarterly, was due on demand and collateralized by substantially all assets of the Company. The average amount of borrowings during the years ended December 31, 2014 (prior to conversion) were $27.4 million. Interest expense related to the note during the year ended December 31, 2014 was $1.1 million. Capital Lease Obligation In December 2014, the Company entered into a new two-year capital lease obligation for laboratory equipment which expires in January 2017, and provides for monthly rent of $7,200. The lease obligations at December 31, 2015 and 2014 were $88,000 and $164,000, which are net of $6,000 and $8,000, respectively, in unamortized discounts. Future maturities of this obligation at December 31, 2015 are $86,000 and $7,000 during 2016 and 2017, respectively. Laboratory equipment with a net book value of $270,000 at December 31, 2015 serves as collateral for this obligation.

Note 5 - Stockholders' Equity

Note 5 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	5. Stockholders’ Equity Preferred Shares The Company has authorized 5,000,000 shares of preferred stock, of which no shares were issued or outstanding at December 31, 2015 or 2014. The Company’s board of directors has the authority to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any class or series, without further vote or action by the stockholders. Common Shares The Company has authorized 50,000,000 shares of common stock, of which 10,635,454 and 3,782,629 shares were issued and outstanding at December 31, 2015 and 2014, respectively. Common shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December 31, 2015 is as follows: Issued and Outstanding: Restricted stock units 351,758 Stock options 631,567 Warrants 203,214 Shares reserved for future award grants 695,260 Total 1,881,799 Public Offerings of Common Stock During September 2015, the Company sold 2,734,983 shares of common stock for total cash proceeds of $4.0 million, which is net of $429,000 in sales agent’s commissions and offering expenses, pursuant to its July 2015 ATM program. Due to the size of the Company’s public float, the current ATM program has been completed, unless and until the Company’s public float increases. On February 20, 2015, the Company completed a public offering of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.8 million, which is net of $1.2 million in underwriter commissions and offering expenses. In connection with the offering, the Company granted a 45-day option to the underwriter to purchase up to 482,142 shares of common stock to cover overallotments, with an aggregate grant date fair value of $132,000. On February 26, 2015, the underwriters exercised the overallotment option for total cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions. In connection with this offering, as a portion of the underwriting compensation payable to the underwriters, the Company issued warrants to purchase 160,714 shares of its common stock to the representative of the underwriters with an aggregate grant date fair value of $198,000. The warrants are exercisable at any time from February 2016 through February 2020 at an exercise price of $3.50 per share. The aggregate fair values of the warrants and overallotment option issued were recorded as an increase to additional paid-in capital with an offset to the proceeds from the offering. The net contribution to additional paid-in capital was $8.7 million after deducting the noncash fair values of warrants and overallotment option issued in connection with the offering. The estimated fair values of the warrants and overallotment option were determined on their respective measurement dates using the BSM option valuation model with the following assumptions: Warrants Overallotment Option Fair value of underlying common stock $ 2.57 $ 2.62 Exercise price $ 3.50 $ 2.60 Risk-free interest rate 1.61 % 0.02 % Volatility 65.5 % 73.0 % Dividend yield 0 % 0 % Contractual term (in years) 5.0 0.12 Weighted-average measurement date fair value per share $ 1.23 $ 0.27 Initial Public Offering On June 23, 2014, the Company completed an IPO of 850,000 shares of its common stock, at $10.00 per share, for total net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash fair values of warrants and option for overallotment shares issued in connection with the IPO. In connection with the IPO in June 2014, the Company issued warrants to certain designees of the underwriter to purchase an aggregate of 42,500 shares of common stock with an aggregate grant date fair value of $143,000. The warrants are exercisable at any time from June 17, 2015 through June 17, 2019. Also, in connection with the IPO, the Company granted a 45-day option to the underwriter to purchase up to 127,500 shares of common stock to cover overallotments, with an aggregate grant date fair value of $157,000. The aggregate fair values of the warrants and stock option issued were recorded as an increase to additional paid-in capital with an offset to the proceeds from the IPO. The estimated fair values of the warrants and stock option award were determined on their respective measurement dates using the BSM option valuation model with the following assumptions: Warrants Options Fair value of common stock $ 7.84 $ 10.00 Exercise price $ 12.50 $ 9.30 Risk-free interest rate 1.72 % 0.035 % Volatility 64.6 % 63.0 % Dividend Yield 0 % 0 % Contractual term (in years) 5.0 0.12 Weighted-average measurement date fair value per share $ 3.38 $ 1.23 Corporate Conversion Immediately prior to the Corporate Conversion, Signal Genetics LLC had issued and outstanding 72,500 Class A units and 41,088 Class B units (23,328 of which were unvested). In connection with the Debt Conversion, on June 17, 2014, the note payable — related party was exchanged for 2,732,629 Class C units of the Company. On June 17, 2014, the outstanding Class A and Class C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for an aggregate of 2,932,629 shares of common stock at $10.00 per share. All outstanding Class B units, which consisted of equity incentive units, were cancelled.

Note 6 - Stock Compensation Pla

Note 6 - Stock Compensation Plan	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6. Stock Compensation Plan The Company’s 2014 Stock Incentive Plan (the “Plan”) provides for stock awards that may be made in the form of incentive or non-statutory stock options, stock appreciation rights, restricted or unrestricted stock awards, restricted stock units, performance awards, or other stock-based awards. No awards may be granted after June 16, 2024. On June 18, 2015, the Company’s stockholders approved the First Amendment to the Plan which provided for an increase in the number of shares of common stock reserved for issuance under the Plan from 1,245,399 to 2,100,000, and an annual increase on the first day of each calendar year, beginning with January 1, 2016 that is equal to the lesser of four percent of the shares of common stock outstanding on the last day of the immediately preceding fiscal year or a smaller number of shares as determined by the board of directors. At December 31, 2015, up to 1,678,585 shares of common stock may be issued under the Plan, of which 983,325 shares are reserved for issuance upon the exercise of outstanding options and vesting of outstanding restricted stock units, and 695,260 shares are available for future grants. Restricted Stock Units (“RSUs”) All of the Company’s outstanding RSU agreements provide for the settlement of the vested RSUs in shares of the Company’s common stock equal to the number of vested RSUs or an amount in cash equal to the product of the fair market value of the common stock on the respective payment date and the number of vested RSUs, or some combination of common shares and cash as determined by the plan administrator as of each settlement date. RSUs generally vest over a period of one to four years, subject to earlier cancellation or forfeiture prior to vesting upon cessation of service to the Company. The total fair value of RSUs that vested during the year ended December 31, 2015 was $734,000. A summary of the activity related to RSUs during year ended December 31, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value per Share Unvested at December 31, 2014 655,200 $ 9.20 Granted 20,000 $ 1.62 Vested (459,208 ) $ 9.23 Unvested at December 31, 2015 215,992 $ 8.43 During the year ended December 31, 2015, the Company issued 421,415 shares in settlement of RSUs that vested in 2015 and 2014. As permitted under the Plan, the Company repurchased 186,920 shares with an aggregate value of $363,000 during the year ended December 31, 2015 to satisfy tax withholding obligations for employees in connection with the vesting of restricted stock units previously granted. Stock Options Stock options generally vest over a four-year period and have a maximum term of ten years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the year ended December 31, 2015 is as follows: Shares Subject to Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2014 152,000 $ 4.53 Granted 513,400 $ 1.60 Forfeitures and cancellations (33,833 ) $ 2.14 Outstanding at December 31, 2015 631,567 $ 2.28 9.4 $ — Options exercisable at December 31, 2015 78,009 $ 3.20 9.1 $ — Options vested and expected to vest as of December 31, 2015 631,567 $ 2.28 9.4 $ — Stock-Based Compensation Expense The estimated fair value of each stock option award was determined on the date of grant using the BSM option valuation model with the following assumptions: Years Ended December 31, 2015 2014 Risk-free interest rate 1.34% - 1.94% 1.73% - 2.03% Expected volatility 58.9% - 67.8% 65.3% - 66.9% Weighted-average volatility 60.2% 66.3% Dividend yield 0% 0% Expected term (in years) 6.0 6.3 Weighted-average grant date fair value per share $0.90 $2.81 The fair value of each stock option is estimated on the date of grant using the BSM option pricing model which requires the input of highly subjective assumptions. Because the option-pricing model is sensitive to change in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. The risk-free interest rate is based on the rate currently available on U.S. Treasury issues with terms approximating the expected term of the option. Due to the Company’s limited historical stock data, the estimated future stock price volatility is based upon the average historical volatilities of a group of peer companies. The Company has not paid any dividends on common stock since the Corporate Conversion and does not anticipate paying dividends on common stock in the foreseeable future. The Company did not issue options prior to the IPO and, therefore, has no history of option exercises. As such, the ‘simplified’ method has been used to estimate the expected term of options. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations is as follows: Years Ended December 31, (in thousands) 2015 2014 Cost of revenue $ 57 $ 257 Selling and marketing 62 16 Research and development 98 121 General and administrative 2,798 3,904 Total $ 3,015 $ 4,298 At December 31, 2015, there was $1.5 million of unamortized compensation cost related to unvested RSUs which is expected to be recognized over a remaining weighted-average vesting period of 1.3 years. At December 31, 2015, there was $628,000 of unamortized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Leases During 2014, the Company entered into a new lease for office space for its corporate headquarters in California, which expires in October 2017. The lease provides for monthly rent of $14,000, which will increase at a rate of 3% annually, and includes three months of rent abatement during the first year with an option to renew the lease for one additional 36-month period. The Company leases a laboratory and office facility under a non-cancellable operating lease agreement, which expires on March 31, 2016. Monthly rent expense is $6,400. Subsequent to December 31, 2015, in February 2016, the Company extended the lease for one year to March 2017, with monthly rent expense of $6,750. Rent expense during the years ended December 31, 2015 and 2014 was $234,000 and $149,000, respectively. In addition, certain administrative functions were performed at an office location leased by the majority stockholder through September of 2014 at no charge to the Company. No amount has been charged for these functions as it is not deemed reasonable to estimate. At December 31, 2015, the future minimum annual obligations under non-cancellable operating lease commitments, excluding the abandoned lease liability described below, are $173,000 and $148,000 during 2016 and 2017, respectively. Lease Abandonment In March 2014, the Company entered into a termination agreement with the landlord of one of its operating leases and agreed to a termination fee of $565,000, payable in monthly installments of $31,400, which were paid in full through August 2015. The present value of the remaining payments under the termination agreement at December 31, 2014 and reported in the consolidated balance sheet was $248,000. The termination agreement resulted in a change in estimate which is reported as an additional expense of $46,000 during the year ended December 31, 2014 and is included in general and administrative expenses in the consolidated statement of operations. Licensing Agreement The Company has a licensing agreement with UAMS for the exclusive use of patents used in the GEP assay, MyPRS ® Services Agreement The Company has a services agreement with a third party to assist with billing and collections from customers through March 2017. The agreement contains automatic one-year renewals, unless a 90-day termination notice is given by either party. Under the terms of the agreement, fees to the third party are based on a percentage of cash collections. The Company has a minimum commitment of $10,000 per month. During the years ended December 31, 2015 and 2014, the Company paid $126,000 and $142,000, respectively, to this vendor. At December 31, 2015, the future minimum commitments under this agreement are $120,000 and $30,000 during the years ended December 31, 2016 and 2017, respectively. Litigation The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. Currently, the Company is not a defendant in any lawsuit. Litigation Settlement In August 2013, the Company settled a lawsuit in which it was the plaintiff for a tortuous interference claim regarding a potential acquisition for a payment of at least $350,000, of which $250,000 was received in January 2014 and the remaining $100,000 was received in January 2015. At December 31, 2014 the Company recorded a receivable for $100,000 in prepaid expenses and other current assets in the consolidated balance sheets, and recognized the related gain for $100,000 during the year ended December 31, 2014.

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. Income Taxes The principal items accounting for the difference in income taxes computed at the federal statutory tax rate of 34% and the effective income tax rate for the Company’s operations during the year ended December 31, 2015 and the period subsequent to the Corporate Conversion on June 17, 2014 through December 31, 2014 are as follows: (in thousands) Year Ended June 17, 2014 to Federal tax at statutory rate $ (3,851 ) $ (2,682 ) Signal Genetics LLC loss, prior to Corporate Conversion, not taxed at corporate level — 425 State taxes, net of federal benefit (277 ) (141 ) Change in valuation allowance 3,625 1,356 Nondeductible compensation 526 1,046 Credits and other (23 ) (4 ) Total provision for income taxes $ — $ — Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, (in thousands) 2015 2014 Deferred Tax Assets: Net operating loss carryforwards $ 3,913 $ 853 Stock-based compensation 810 463 Accrued compensation 257 74 Deferred rent 14 — Credit carryforward 52 6 Total deferred tax assets 5,046 1,396 Valuation allowance (4,696 ) (1,196 ) Deferred tax assets, net of valuation allowance 350 200 Deferred tax liabilities: Depreciation and amortization (350 ) (200 ) Net deferred tax assets $ — $ — A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. Based on the available evidence at December 31, 2015 and 2014, the Company was not able to conclude that it is more likely than not certain deferred tax assets will be realized, and, therefore, recorded valuation allowances of $4.7 million and $1.2 million, respectively, against deferred tax assets. As of December 31, 2015, the Company had operating loss carryforwards for federal and state tax purposes of $10.6 million each, which will begin to expire in 2035. In addition, the Company has $52,000 in federal tax credits at December 31, 2015 that will begin to expire in 2035. Internal Revenue Code Sections 382 and 383 limit the availability of income tax net operating losses and tax credit carryforwards that arise prior to certain cumulative changes in a corporation's ownership resulting in change of control of the Company should such changes in ownership occur. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within a three-year period. The Company’s 2015 and 2014 tax years remain open to examination by one or more major taxing jurisdictions to which the Company is subject.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, accounts receivable and allowance for doubtful accounts, accounting for income taxes, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash is comprised of cash on hand and deposits in banks. The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents, which, at December 31, 2015, are comprised of money market funds. At December 31, 2014, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease. The restriction was removed during 2015 and the cash balance transferred into the Company’s money market account.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable, and Contractual Allowances and Allowance for Doubtful Accounts Accounts receivable are recorded net of contractual allowances and an allowance for doubtful accounts. At December 31, 2015 and 2014, contractual allowances were $2.1 million and $1.5 million, respectively. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. During the years ended December 31, 2015 and 2014, the Company recognized $33,000 and $177,000 in bad debt expense, respectively. At December 31, 2015 and 2014, there were no allowances for doubtful accounts.
Inventory, Policy [Policy Text Block]	Inventory Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in operations.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long Lived Assets Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years ended December 31, 2015 or 2014.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs During the year ended December 31, 2014, the Company incurred $47,000 in direct costs related to its anticipated public offering of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and reclassified as a reduction to additional paid-in capital upon completion of the 2015 Offering.
Lease, Policy [Policy Text Block]	Deferred Rent Where rent abatements are made available to the Company under the terms of a lease agreement, the abatements are accounted for as a reduction of rent expense over the life of the lease and rent expense is recognized on a straight-line basis over the entire term of the lease. The cumulative difference between actual rent payments and recognized rental expense is recorded as deferred rent in the consolidated balance sheets.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Revenues are recorded on an accrual basis when the contractual obligations are completed as tests are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced at the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate, and anticipated effects of changes in the healthcare industry, if any. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date. The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and anticipated changes in the healthcare industry and adjusts expected revenues for current and subsequent periods accordingly. During the year ended December 31, 2015, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $193,000. During the year ended December 31, 2014, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000 and $274,000 related to revenues previously recorded during 2012 and 2013, respectively. The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations: Years Ended December 31, (in thousands) 2015 2014 Gross revenues $ 5,706 $ 6,484 Less: contractual allowances (3,168 ) (2,164 ) Net revenue $ 2,538 $ 4,320 Contractual allowances recorded during the years ended December 31, 2015 and 2014 represented 56% and 33% of gross revenues, respectively. The increase in the contractual allowances is due to changes in the Company’s estimates of net revenue for non-contracted payors based on the contractual status and payment policies of the payors, and anticipated changes in the healthcare industry.
Cost of Sales, Policy [Policy Text Block]	Cost of Revenue Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result, depreciation, amortization and royalty expense. Costs associated with performing tests are recorded as the tests are processed.
License Fees Policy [Policy Text Block]	Royalties The Company licenses technology for patents for uses of a gene expression profiling (“GEP”) assay called MyPRS ®
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs associated with research and development activities are expensed as incurred. Research and development costs primarily include personnel costs, laboratory supplies, reagents, consulting and sponsored research agreements.
Income Tax, Policy [Policy Text Block]	Income Taxes Prior to the Corporate Conversion, the Company was a limited liability company, which is not a tax paying entity at the corporate level. Each member was instead individually responsible for such member’s share of the Company’s income or loss for income tax reporting purposes. Net operating losses incurred by the Company through the date of the Corporate Conversion have been, or will be, used by the members to offset gains on other interests and are, therefore, not able to be carried forward to the Company. Effective as of the Corporate Conversion, deferred tax assets and liabilities are recorded for the expected future tax consequences of events that have been included in the consolidated financial statements or income tax returns. Deferred taxes are determined on the basis of the differences between the carrying amount of assets and liabilities for financial statement and income tax purposes, as well as tax credit and net operating loss carryforwards, at enacted rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. Applicable accounting guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Accounting provisions also require that a change in judgment that results in subsequent recognition, derecognition, or change in a measurement of a tax position taken in a prior annual period (including any related interest and penalties) be recognized as a discrete item in the period in which the change occurs. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available. Any interest and penalties related to unrecognized tax benefits are classified as a component of income tax expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees and directors is estimated at the date of grant. The fair value of restricted stock units issued to employees and directors is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. For stock-based compensation awards granted to non-employees, the fair value of the awards are remeasured at each reporting date until vested, with changes in the estimated fair value recognized as an adjustment to compensation expense in the period of change. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense. Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company’s financial instruments that are measured at fair value on a recurring basis consist principally of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and note payable-related party. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Includes other inputs that are directly or indirectly observable in the marketplace. Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. At December 31, 2015 and 2014, the Company’s cash equivalent instruments consisted of $10.4 million and $0, respectively, in a money market fund which is reported at fair value using Level 1 inputs. The carrying amounts of financial instruments such as restricted cash, accounts receivable, accounts payable and note payable-related party approximate their relative fair values due to the short-term maturities and market rates of interest of these instruments. At December 31, 2014, the fair value of the Company’s remaining lease liability on its vacated facility, which was paid in full during 2015, was measured using estimated net cash flows, discounted using a nominal risk-free rate, which are considered Level 3 inputs. The present value of the remaining lease liability at December 31, 2014 was $248,000.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting. Common stock equivalents, determined on a weighted-average outstanding basis, that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows: December 31, 2015 2014 Unvested restricted stock units 431,088 655,200 Options to purchase common stock 355,215 152,000 Warrants to purchase common stock 180,446 42,500 Total 966,749 849,700
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk, Major Customers and Suppliers Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances. The Company invests excess cash in money market funds under the custodianship of a major financial institution. This diversification of risk is consistent with the Company's policy to ensure safety of principal and maintain liquidity. The Company had two major customers, UAMS and H. Lee Moffitt Cancer Center and Research Institute (“Moffitt”). Revenue sourced either from or through UAMS accounted for 54% and 84% of net revenue during the years ended December 31, 2015 and 2014, respectively, and revenue sourced through Moffitt accounted for 10% and 9% of net revenue during the years ended December 31, 2015 and 2014 respectively. Accounts receivable from UAMS at December 31, 2015 and 2014 accounted for 19% and 42%, respectively, of total accounts receivable outstanding. At December 31, 2015 and 2014 the Company had no accounts receivable from Moffitt. Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business.
Reclassification, Policy [Policy Text Block]	Reclassifications Reclassifications of certain operating expenses in the consolidated statement of operations have been made to year ended December 31, 2014 to conform to the 2015 presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, which replaces the existing accounting guidance for leases. This standard requires entities that lease assets to recognize the assets and liabilities for the rights and obligations created by those leases on the balance sheet. The standard is effective for fiscal years and the interim periods within those fiscal years beginning after December 15, 2018. The guidance is required to be applied by the modified retrospective transition approach and early adoption is permitted. The Company is currently assessing the impact that adoption of this guidance will have on its consolidated financial statements and footnote disclosures. In July 2015, the FASB issued ASU 2015-11, which simplifies the measurement of inventories valued under most methods, including the Company’s inventories valued under the FIFO method. Under this new guidance, inventories valued under these methods would be valued at the lower of cost and net realizable value, with net realizable value defined as the estimated selling price less reasonable costs to sell the inventory. The new guidance is effective prospectively for the Company’s quarterly reporting period beginning January 1, 2017, with early adoption permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and was originally effective for the Company’s annual reporting period beginning January 1, 2018, including interim periods within that reporting period. In July 2015, the FASB voted to defer the effective date of this ASU by one year, which is effective for the Company’s annual reporting period beginning January 1, 2019, with early adoption permitted beginning with the annual reporting period ending December 31, 2017. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period ending December 31, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. Future Accounting Pronouncements Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company, such as the Company, may take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although, to date, the Company has not taken advantage of this delay, the Company has elected to avail itself of the extended transition period for adopting new or revised accounting standards in the future. As a result of this election, the Company’s consolidated financial statements may not be comparable to companies that comply with public company effective dates.

Note 2 - Significant Accounti16

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Reconciliation of Gross Revenues to Net Revenues [Table Text Block]	Years Ended December 31, (in thousands) 2015 2014 Gross revenues $ 5,706 $ 6,484 Less: contractual allowances (3,168 ) (2,164 ) Net revenue $ 2,538 $ 4,320
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2015 2014 Unvested restricted stock units 431,088 655,200 Options to purchase common stock 355,215 152,000 Warrants to purchase common stock 180,446 42,500 Total 966,749 849,700

Note 3 - Balance Sheet Accoun17

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 2015 2014 Laboratory and computer equipment $ 1,817 $ 1,711 Furniture and fixtures 69 52 Leasehold improvements 6 6 1,892 1,769 Less: accumulated depreciation and amortization (739 ) (555 ) Total property and equipment, net $ 1,153 $ 1,214
Schedule of Accrued Liabilities [Table Text Block]	December 31, (in thousands) 2015 2014 Accrued bonuses $ 592 $ 183 Accrued compensation and related expenses 234 74 Accrued interest payable – related party 73 — Accrued contract research and development 35 — Accrued offering costs — 42 Other 84 62 Total accrued expenses $ 1,018 $ 361

Note 5 - Stockholders' Equity (

Note 5 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]	Issued and Outstanding: Restricted stock units 351,758 Stock options 631,567 Warrants 203,214 Shares reserved for future award grants 695,260 Total 1,881,799
Schedule Of Share Based Payment Award Nonemployee Valuation Assumptions [Table Text Block]	Warrants Overallotment Option Fair value of underlying common stock $ 2.57 $ 2.62 Exercise price $ 3.50 $ 2.60 Risk-free interest rate 1.61 % 0.02 % Volatility 65.5 % 73.0 % Dividend yield 0 % 0 % Contractual term (in years) 5.0 0.12 Weighted-average measurement date fair value per share $ 1.23 $ 0.27 Warrants Options Fair value of common stock $ 7.84 $ 10.00 Exercise price $ 12.50 $ 9.30 Risk-free interest rate 1.72 % 0.035 % Volatility 64.6 % 63.0 % Dividend Yield 0 % 0 % Contractual term (in years) 5.0 0.12 Weighted-average measurement date fair value per share $ 3.38 $ 1.23

Note 6 - Stock Compensation P19

Note 6 - Stock Compensation Plan (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Number of Shares Weighted-Average Grant Date Fair Value per Share Unvested at December 31, 2014 655,200 $ 9.20 Granted 20,000 $ 1.62 Vested (459,208 ) $ 9.23 Unvested at December 31, 2015 215,992 $ 8.43
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Subject to Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2014 152,000 $ 4.53 Granted 513,400 $ 1.60 Forfeitures and cancellations (33,833 ) $ 2.14 Outstanding at December 31, 2015 631,567 $ 2.28 9.4 $ — Options exercisable at December 31, 2015 78,009 $ 3.20 9.1 $ — Options vested and expected to vest as of December 31, 2015 631,567 $ 2.28 9.4 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years Ended December 31, 2015 2014 Risk-free interest rate 1.34% - 1.94% 1.73% - 2.03% Expected volatility 58.9% - 67.8% 65.3% - 66.9% Weighted-average volatility 60.2% 66.3% Dividend yield 0% 0% Expected term (in years) 6.0 6.3 Weighted-average grant date fair value per share $0.90 $2.81
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Years Ended December 31, (in thousands) 2015 2014 Cost of revenue $ 57 $ 257 Selling and marketing 62 16 Research and development 98 121 General and administrative 2,798 3,904 Total $ 3,015 $ 4,298

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	(in thousands) Year Ended June 17, 2014 to Federal tax at statutory rate $ (3,851 ) $ (2,682 ) Signal Genetics LLC loss, prior to Corporate Conversion, not taxed at corporate level — 425 State taxes, net of federal benefit (277 ) (141 ) Change in valuation allowance 3,625 1,356 Nondeductible compensation 526 1,046 Credits and other (23 ) (4 ) Total provision for income taxes $ — $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, (in thousands) 2015 2014 Deferred Tax Assets: Net operating loss carryforwards $ 3,913 $ 853 Stock-based compensation 810 463 Accrued compensation 257 74 Deferred rent 14 — Credit carryforward 52 6 Total deferred tax assets 5,046 1,396 Valuation allowance (4,696 ) (1,196 ) Deferred tax assets, net of valuation allowance 350 200 Deferred tax liabilities: Depreciation and amortization (350 ) (200 ) Net deferred tax assets $ — $ —

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual) - USD ($)	Feb. 26, 2015	Feb. 20, 2015	Jun. 23, 2014	Jun. 17, 2014	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Jun. 17, 2017	Jul. 10, 2015
ATM Program [Member]
Other Commitment									$ 4,450,000
Stock Issued During Period, Shares, New Issues					2,734,983	2,734,983
Proceeds from Issuance of Common Stock					$ 4,000,000	$ 4,000,000
Payments of Stock Issuance Costs					$ 429,000	$ 429,000
Over-Allotment Option [Member] | Underwriter Options [Member]
Payments of Stock Issuance Costs	$ 95,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	482,142	482,142
Proceeds from Stock Options Exercised	$ 1,300,000
IPO [Member] | Underwriter Options [Member]
Share Price						$ 10
IPO [Member]
Stock Issued During Period, Shares, New Issues			850,000
Payments of Stock Issuance Costs			$ 2,400,000
Share Price			$ 10
Proceeds from Issuance Initial Public Offering			$ 6,100,000
Adjustments to Additional Paid in Capital, Other			$ 5,800,000
Conversion of Class C Units [Member]
Debt Conversion, Converted Instrument, Shares Issued				2,732,629
Conversion of Class A Units [Member]
Stock Issued During Period, Shares, Conversion of Units				200,000
Capital Unit, Class C [Member]
Debt Conversion, Converted Instrument, Shares Issued				2,732,629				2,732,629
Stock Issued During Period, Shares, Conversion of Units				2,732,629
Stock Issued During Period, Shares, New Issues		3,214,285
Proceeds from Issuance of Common Stock		$ 7,800,000				$ 13,095,000	$ 6,644,000
Payments of Stock Issuance Costs		$ 1,200,000
Share Price		$ 2.80		$ 10
Debt Conversion, Original Debt, Amount				$ 27,300,000
Stock Issued During Period, Shares, Conversion of Units				2,932,629
Adjustments to Additional Paid in Capital, Other		$ 8,700,000

Note 2 - Significant Accounti22

Note 2 - Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Moffitt Cancer Center [Member]
Accounts Receivable, Net, Current	$ 0	$ 0
Customer Concentration Risk [Member] | Accounts Receivable [Member] | UAMS [Member]
Concentration Risk, Percentage	19.00%	42.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Moffitt Cancer Center [Member]
Concentration Risk, Percentage	10.00%	9.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | UAMS [Member]
Concentration Risk, Percentage	54.00%	84.00%
Customer Concentration Risk [Member]
Number of Major Customers	2
Supplier Concentration Risk [Member]
Number of Major Suppliers	1
Letter of Credit [Member]
Restricted Cash and Cash Equivalents, Current		$ 50,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Sales Returns and Allowances [Member] | Recorded in 2012 [Member]
Estimated Contracted Revenues Adjustment		106,000
Sales Returns and Allowances [Member] | Recorded in 2013 [Member]
Estimated Contracted Revenues Adjustment		274,000
Sales Returns and Allowances [Member]
Estimated Non-Contracted Revenues Adjustment	$ 193,000	380,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash Equivalents, at Carrying Value	10,400,000	0
Fair Value, Inputs, Level 3 [Member] | Property Available for Operating Lease [Member]
Commitments, Fair Value Disclosure		248,000
Allowance for Doubtful Accounts Receivable	0	0
Impairment of Long-Lived Assets Held-for-use	0	0
Accounts Receivable, Net, Current	394,000	1,088,000
Contractual Allowance	2,100,000	1,500,000
Provision for Doubtful Accounts	$ 33,000	177,000
Deferred Offering Costs		$ 47,000
Contractual Allowances Percentage	56.00%	33.00%

Note 2 - Adjustments Made to Gr

Note 2 - Adjustments Made to Gross Revenues to Arrive at Net Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Gross revenues	$ 5,706	$ 6,484
Less: contractual allowances	(3,168)	(2,164)
Net revenue	$ 2,538	$ 4,320

Note 2 - Antidilutive Securitie

Note 2 - Antidilutive Securities Excluded from Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Anti-dilutive Securities (in shares)	431,088	655,200
Stock Option [Member]
Anti-dilutive Securities (in shares)	355,215	152,000
Warrant [Member]
Anti-dilutive Securities (in shares)	180,446	42,500
Anti-dilutive Securities (in shares)	966,749	849,700

Note 3 - Balance Sheet Accoun25

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Laboratory and Computer Equipment [Member]
Capital Leased Assets, Gross	$ 300,000	$ 300,000

Note 3 - Property and Equipment

Note 3 - Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Laboratory and Computer Equipment [Member]
Property, plant, and equipment	$ 1,817,000	$ 1,711,000
Furniture and Fixtures [Member]
Property, plant, and equipment	69,000	52,000
Leasehold Improvements [Member]
Property, plant, and equipment	6,000	6,000
Property, plant, and equipment	1,892,000	1,769,000
Less: accumulated depreciation and amortization	(739,000)	(555,000)
Total property and equipment, net	$ 1,153,000	$ 1,214,000

Note 3 - Accrued Expenses (Deta

Note 3 - Accrued Expenses (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Due To Related Party Converted To Unsecured Note Payable [Member]
Interest Payable, Current	$ 73,000
Accrued bonuses	592,000	$ 183,000
Accrued compensation and related expenses	234,000	$ 74,000
Accrued contract research and development	$ 35,000
Accrued offering costs		$ 42,000
Other	$ 84,000	62,000
Total accrued expenses	$ 1,018,000	$ 361,000

Note 4 - Amount Due Related P28

Note 4 - Amount Due Related Party, Notes Payable and Capital Lease Obligations (Details Textual) - USD ($)	Mar. 06, 2015	Jun. 17, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 17, 2017	Jun. 30, 2014
Due To Related Party Converted To Unsecured Note Payable [Member] | Accrued Liabilities [Member]
Interest Payable, Current			$ 73,000
Due To Related Party Converted To Unsecured Note Payable [Member]
Debt Conversion, Original Debt, Amount	$ 1,045,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Increase (Decrease), Net	$ 60,000
Notes Payable, Related Parties, Current	$ 1,105,000		1,105,000
Related Party Transaction, Rate	8.00%
Interest Expense, Related Party			132,000
Interest Payable, Current			73,000
Advance to Pay for Certain Offering Expenses [Member] | Majority Shareholder [Member] | Unsecured Note Payable [Member]
Increase (Decrease) in Notes Payable, Related Parties		$ 45,000
Majority Shareholder [Member] | Secured Note Payable [Member]
Debt Conversion, Original Debt, Amount		27,300,000
Interest Expense, Related Party				$ 1,100,000
Short-term Debt, Average Outstanding Amount				27,400,000
Majority Shareholder [Member] | Unsecured Note Payable [Member]
Increase (Decrease) in Notes Payable, Related Parties		$ 1,000,000
Majority Shareholder [Member] | Interest Rate Compounded Quarterly [Member]
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Majority Shareholder [Member]
Proceeds from Related Party Debt				$ 795,000
Capital Unit, Class C [Member]
Debt Conversion, Converted Instrument, Shares Issued		2,732,629			2,732,629
Laboratory and Computer Equipment [Member]
Debt Instrument, Collateral Amount			270,000
Debt Conversion, Original Debt, Amount		$ 27,300,000
Notes Payable, Related Parties, Current			1,105,000
Proceeds from Related Party Debt				$ 795,000
Capital Lease Obligation Term				2 years
Capital Lease Obligations Monthly Rent				$ 7,200
Capital Lease Obligations			88,000	164,000
Capital Lease Obligation Unamortized Discount			6,000	$ 8,000
Capital Leases, Future Minimum Payments Due, Next Twelve Months			86,000
Capital Leases, Future Minimum Payments Due in Two Years			$ 7,000

Note 5 - Stockholders' Equity29

Note 5 - Stockholders' Equity (Details Textual) - USD ($)	Feb. 26, 2015	Feb. 20, 2015	Jun. 23, 2014	Jun. 17, 2014	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Jun. 17, 2017	Jun. 14, 2014
Capital Unit, Class C [Member]
Limited Partners' Capital Account, Units Outstanding									72,500
Limited Partners' Capital Account, Units Issued									72,500
Debt Conversion, Converted Instrument, Shares Issued				2,732,629				2,732,629
Stock Issued During Period, Shares, Conversion of Units				2,732,629
Capital Unit, Class B [Member] | Unvested [Member]
Limited Partners' Capital Account, Units Outstanding									23,328
Capital Unit, Class B [Member]
Limited Partners' Capital Account, Units Outstanding									41,088
Limited Partners' Capital Account, Units Issued									41,088
Capital Unit, Class A [Member]
Stock Issued During Period, Shares, Conversion of Units				200,000
ATM Program [Member]
Stock Issued During Period, Shares, New Issues					2,734,983	2,734,983
Proceeds from Issuance of Common Stock					$ 4,000,000	$ 4,000,000
Payments of Stock Issuance Costs					$ 429,000	$ 429,000
Over-Allotment Option [Member] | Underwriter Options [Member]
Payments of Stock Issuance Costs	$ 95,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	482,142	482,142
Proceeds from Stock Options Exercised	$ 1,300,000
IPO [Member] | Underwriter Options [Member]
Share Price						$ 10
IPO [Member]
Stock Issued During Period, Shares, New Issues			850,000
Payments of Stock Issuance Costs			$ 2,400,000
Share Price			$ 10
Adjustments to Additional Paid in Capital, Other			$ 5,800,000
Proceeds from Issuance Initial Public Offering			$ 6,100,000
Underwriter Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		45 days	45 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 132,000	$ 157,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			127,500
Common Stock, Shares, Outstanding						10,635,454	3,782,629
Preferred Stock, Shares Issued						0	0
Preferred Stock, Shares Outstanding						0	0
Common Stock, Shares Authorized						50,000,000	50,000,000
Preferred Stock, Shares Authorized						5,000,000	5,000,000
Common Stock, Shares, Issued						10,635,454	3,782,629
Stock Issued During Period, Shares, New Issues		3,214,285
Proceeds from Issuance of Common Stock		$ 7,800,000				$ 13,095,000	$ 6,644,000
Payments of Stock Issuance Costs		$ 1,200,000
Share Price		$ 2.80		$ 10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		160,714	42,500
Issuance of Stock and Warrants for Services or Claims		$ 198,000	$ 143,000			$ 330,000	$ 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.50
Adjustments to Additional Paid in Capital, Other		$ 8,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						513,400
Stock Issued During Period, Shares, Conversion of Units				2,932,629

Note 5 - Common Shares Reserved

Note 5 - Common Shares Reserved for Future Issuance (Details)	Dec. 31, 2015shares
Restricted Stock Units (RSUs) [Member]
Restricted stock units (in shares)	351,758
Stock options (in shares)	631,567
Warrants (in shares)	203,214
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	695,260
Total (in shares)	1,881,799

Note 5 - BSM Option Valuation M

Note 5 - BSM Option Valuation Model Assumptions (Details)	12 Months Ended
	Dec. 31, 2015$ / shares
Warrant [Member] | Public Offerings [Member]
Share Price	$ 2.57
Exercise price (in dollars per share)	$ 3.50
Risk-free interest rate	1.61%
Volatility	65.50%
Dividend yield	0.00%
Contractual term (in years)	5 years
Weighted-average measurement date fair value per share (in dollars per share)	$ 1.23
Warrant [Member] | IPO [Member]
Share Price	7.84
Exercise price (in dollars per share)	$ 12.50
Risk-free interest rate	1.72%
Volatility	64.60%
Dividend yield	0.00%
Contractual term (in years)	5 years
Weighted-average measurement date fair value per share (in dollars per share)	$ 3.38
Public Offerings [Member] | Underwriter Options [Member]
Share Price	2.62
Exercise price (in dollars per share)	$ 2.60
Risk-free interest rate	0.02%
Volatility	73.00%
Dividend yield	0.00%
Contractual term (in years)	43 days
Weighted-average measurement date fair value per share (in dollars per share)	$ 0.27
IPO [Member] | Underwriter Options [Member]
Share Price	10
Exercise price (in dollars per share)	$ 9.30
Risk-free interest rate	0.035%
Volatility	63.00%
Dividend yield	0.00%
Contractual term (in years)	43 days
Weighted-average measurement date fair value per share (in dollars per share)	$ 1.23

Note 6 - Stock Compensation P32

Note 6 - Stock Compensation Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Jun. 18, 2015	Jun. 17, 2015
The Plan [Member] | Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
The Plan [Member] | Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
The Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 734,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	421,415
Shares Paid for Tax Withholding for Share Based Compensation	186,920
Adjustments Related to Tax Withholding for Share-based Compensation	$ 363,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 109 days
The Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
The Plan [Member] | Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 628,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 292 days
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,678,585	2,100,000	1,245,399
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Common Stock Outstanding	4.00%
Share Based Compensation Arrangement By Share Based Payment Award Number Of Awards Outstanding	983,325
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	695,260
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	695,260

Note 6 - Restricted Stock Units

Note 6 - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Shares Unvested, Beginning Balance (in shares) | shares	655,200
Weighted-average Grant Date Fair Value Per Share, Unvested, Beginning Balance (in dollars per share) | $ / shares	$ 9.20
Shares Granted (in shares) | shares	20,000
Weighted-average Grant Date Fair Value Per Share, Granted (in dollars per share) | $ / shares	$ 1.62
Shares Vested (in shares) | shares	(459,208)
Weighted-average Grant Date Fair Value Per Share, Vested (in dollars per share) | $ / shares	$ 9.23
Shares Unvested, Ending Balance (in shares) | shares	215,992
Weighted-average Grant Date Fair Value Per Share, Unvested, Ending Balance (in dollars per share) | $ / shares	$ 8.43

Note 6 - Stock Options Activity

Note 6 - Stock Options Activity (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Shares Subject to Options, Outstanding, Beginning Balance (in shares) | shares	152,000
Weighted-average Exercise Price Per Share, Outstanding, Beginning Balance (in dollars per share) | $ / shares	$ 4.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	513,400
Weighted-average Exercise Price Per Share, Granted (in dollars per share) | $ / shares	$ 1.60
Shares Subject to Options, Forfeitures and Cancellations (in shares) | shares	(33,833)
Weighted-average Exercise Price Per Share, Forfeitures and Cancellations (in dollars per share) | $ / shares	$ 2.14
Shares Subject to Options, Outstanding, Ending Balance (in shares) | shares	631,567
Weighted-average Exercise Price Per Share, Outstanding, Ending Balance (in dollars per share) | $ / shares	$ 2.28
Weighted-average Remaining Contractual Term, Outstanding	9 years 146 days
Shares Subject to Options, Exercisable (in shares) | shares	78,009
Weighted-average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares	$ 3.20
Weighted-average Remaining Contractual Term, Exercisable	9 years 36 days
Shares Subject to Options, Vested and Expected to Vest (in shares) | shares	631,567
Weighted-average Exercise Price Per Share, Vested and Expected to Vest (in dollars per share) | $ / shares	$ 2.28
Weighted-average Remaining Contractual Term, Vested and Expected to Vest	9 years 146 days

Note 6 - BSM Option Valuation M

Note 6 - BSM Option Valuation Model Assumptions (Details) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Minimum [Member]
Risk-free interest rate	1.34%	1.73%
Expected volatility	58.90%	65.30%
Maximum [Member]
Risk-free interest rate	1.94%	2.03%
Expected volatility	67.80%	66.90%
Weighted-average volatility	60.20%	66.30%
Dividend yield	0.00%	0.00%
Expected term (in years)	6 years	6 years 109 days
Weighted-average grant date fair value per share (in dollars per share)	$ 0.90	$ 2.81

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation Expense Allocation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cost of Sales [Member]
Allocated Share Based Compensation Expense	$ 57	$ 257
Selling and Marketing Expense [Member]
Allocated Share Based Compensation Expense	62	16
Research and Development Expense [Member]
Allocated Share Based Compensation Expense	98	121
General and Administrative Expense [Member]
Allocated Share Based Compensation Expense	2,798	3,904
Allocated Share Based Compensation Expense	$ 3,015	$ 4,298

Note 7 - Commitments and Cont37

Note 7 - Commitments and Contingencies (Details Textual)	1 Months Ended					12 Months Ended
	Feb. 29, 2016USD ($)	Jan. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Jan. 31, 2014USD ($)	Aug. 31, 2013USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Lease for Office Space for Corporate Headquarters [Member]
Monthly Rent Expense						$ 14,000
Lease and Rental Expense, Annual Increase, Percentage						3.00%
Lessee Leasing Arrangements, Operating Leases, Renewal Term						3 years
Lease for Laboratory and Office Facility [Member] | Subsequent Event [Member]
Monthly Rent Expense	$ 6,750
Lessee Leasing Arrangements, Operating Leases, Renewal Term	1 year
Lease for Laboratory and Office Facility [Member]
Monthly Rent Expense						$ 6,400
Termination Agreement [Member]
Lease Termination Abandonment Payable			$ 565,000
Lease Termination Abandonment Balance Payable, Monthly Installments			$ 31,400
Lease Termination Abandonment Payable Current							$ 248,000
Service Agreement for Billing and Collections [Member]
Monthly Purchase Obligation						10,000
Payments for Fees						126,000	142,000
Purchase Obligation, Due in Next Twelve Months						120,000
Purchase Obligation, Due in Second Year						$ 30,000
General and Administrative Expense [Member]
Changed In Estimate, Reported as Additional Expense							46,000
Minimum [Member]
Percentage of Annual Minimum Royalty Fees						2.00%
Maximum [Member]
Percentage of Annual Minimum Royalty Fees						4.00%
Prepaid Expenses and Other Current Assets [Member]
Accounts and Other Receivables, Net, Current							100,000
Royalty Expense						$ 30,000	30,000
Operating Leases, Rent Expense, Net						234,000	149,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months						173,000
Operating Leases, Future Minimum Payments, Due in Two Years						$ 148,000
Operating Leases, Abandoned Number			1
Lease Termination Abandonment Payable Current							248,000
Royalty Guarantees, Commitments, Amount						$ 30,000
Litigation Settlement, Amount					$ 350,000
Proceeds from Legal Settlements		$ 100,000		$ 250,000
Gain (Loss) Related to Litigation Settlement							$ 100,000

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Earliest Tax Year [Member]
Open Tax Year	2,015
Latest Tax Year [Member]
Open Tax Year	2,014
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 10,600,000
Domestic Tax Authority [Member]
Deferred Tax Assets, Tax Credit Carryforwards	$ 52,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Deferred Tax Assets, Valuation Allowance	$ 4,696,000	$ 1,196,000
Deferred Tax Assets, Tax Credit Carryforwards	$ 52,000	$ 6,000

Note 8 - Effective Income Tax R

Note 8 - Effective Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Predecessor [Member]
Federal tax at statutory rate		$ 425,000
Federal tax at statutory rate	$ (3,851,000)	(2,682,000)
State taxes, net of federal benefit	(277,000)	(141,000)
Change in valuation allowance	3,625,000	1,356,000
Nondeductible compensation	526,000	1,046,000
Credits and other	(23,000)	(4,000)
Total provision for income taxes	$ 0	$ 0

Note 8 - Deferred Tax Assets an

Note 8 - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets:
Net operating loss carryforwards	$ 3,913,000	$ 853,000
Stock-based compensation	810,000	463,000
Accrued compensation	257,000	$ 74,000
Deferred rent	14,000
Deferred Tax Assets, Tax Credit Carryforwards	52,000	$ 6,000
Total deferred tax assets	5,046,000	1,396,000
Valuation allowance	(4,696,000)	(1,196,000)
Deferred tax assets, net of valuation allowance	350,000	200,000
Deferred tax liabilities:
Depreciation and amortization	(350,000)	(200,000)
Net deferred tax assets	$ 0	$ 0